We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A shakeup is swirling through the cholesterol market, one of the most profitable for the drug industry in recent years, as two mainstays have been hit by generic competition this year and giant Pfizer Inc. is rushing to protect its Lipitor franchise.
Several large U.S. drug makers are expected to report improved third-quarter profits, helped by cost cuts, the Medicare drug benefit and growing sales of newer products.
When scientific advisers urged the Food and Drug Administration in February to put a warning about suspected heart risks on attention-deficit drugs taken by millions of children and adults, agency officials said that more clinical evidence was needed.
Tuesday, GeoPharma, Inc., a pharmaceutical company, said Schering-Plough has filed a lawsuit against the company and its subsidiary Belcher Pharmaceuticals, Inc. alleging that a generic version of Clarinex Desloratadine 5 mg tablets from GeoPharma infringes patent.
Genzyme Corporation announced that it has informed the Board of Directors of AnorMED Inc. that it is prepared to increase its offer to acquire all outstanding shares of AnorMED to US $13.50 per share, or approximately $580 million, contingent upon AnorMED executing a support agreement with Genzyme.
Gilead Sciences is seeking to beef up its drug pipeline and its emphasis on treatments for pulmonary conditions, announcing Oct. 2 it will acquire Myogen for $2.5 billion.
Successfully heading off a preliminary injunction or temporary restraining order halting sales of a generic drug requires quickly convincing the judge why such a move would be harmful to the generic company, according to a legal expert.
The government's effort to compare different drug products is moving forward, with the NIH's National Eye Institute funding a clinical trial comparing two drugs used to treat advanced age-related macular degeneration (AMD), the leading cause of blindness among the elderly.
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) announce that they received court decisions on ANDA-related summary judgment motions for Aciphex (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet) on October 6, 2006.